To our global community,

Progress in healthcare doesn’t happen by chance. It takes innovation, bold ambition and relentless execution.

Our annual Health for Humanity Report highlights the work Johnson & Johnson is doing to tackle the world’s toughest health challenges.

The year 2025 propelled Johnson & Johnson into a new era of accelerated impact and growth. We continued to sharpen our focus in six areas of high-growth and high-unmet medical need: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. As part of this strategic focus, we announced the planned separation of our Orthopaedics business. Our unique business model spans both Innovative Medicine and MedTech, giving us the depth and scale to shape the future of healthcare in ways no other company can. With $32 billion invested in R&D and strategic acquisitions, we have the strongest portfolio and pipeline in our 140-year history.

The energy, determination and skill of our global teams, grounded in a shared commitment to Our Credo values, powered our progress and delivered meaningful change for patients around the world.

The Company advanced health outcomes in lasting ways by reaching 1.7 million healthcare workers with tools, training and support to improve quality care. We also remain focused on caring for our people, environmental stewardship and strong accountability and governance.

Our employees are deeply committed to making a difference: 94% say they are willing to go the extra mile to help Johnson & Johnson succeed. In turn, we care for them by investing in their continued growth and well-being. More than 420,000 hours of learning were logged during our Global Learning Day, and more than 30,000 colleagues took part in our Global Activity Challenge.

To build a healthier, more resilient world, our ongoing environmental stewardship resulted in the sourcing of 100% renewable electricity to meet our operational electricity needs worldwide and a 38% reduction in greenhouse gas emissions since 2021.

In parallel, our accountability and governance safeguards protected patients and continued to guide how we operate. We trained 3,900 law enforcement and government officials to protect patients from counterfeit products and we directed more than $2.3 billion to small businesses in the U.S. to broaden economic opportunity.

These accomplishments reflect our resolve to put patients at the center of everything we do as we continue to deliver meaningful, lasting impact for the people who depend on us.

I invite you to explore the full report for more information on how our teams are translating Our Credo into action around the world.